Boehringer and Lilly’s Jardiance Hits Mark in Decreasing Risk of Death in Heart Failure

Boehringer Ingelheim and Eli Lilly and Company announced that the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, met the primary endpoint. Jardiance (empagliflozin) was superior to placebo in decreasing the risk of a composite of cardiovascular death or hospitalization from heart failure when added to standard of care.